Stroke Thrombectomy Access in Cancer: Yielding better Home Outcomes and decreased Morbidity: STAY-HOME-Cancer

Thrombectomy to remove clot obstructing the large vessel represents the most powerful treatment for ischaemic stroke due to large vessel occlusion (LVO) and has been confirmed to be effective in multiple randomised control trials since 20151. This treatment has resulted in 40%-50% of patients returning home within one week of stroke. The idea behind the design of those early trials was to establish the efficacy of thrombectomy and hence they used restrictive inclusion criteria. Since 2015, the number of patients being referred for thrombectomy have increased through the years. However, the proportion of patients with active cancer receiving thrombectomy in stroke registry is low (4.8%). One explanation is that the earlier trials have excluded these patients and have created uncertainty in clinical decisions. Exclusion of these patients from trials have occurred due to fear that the poor outcome from cancer would confound the success of thrombectomy. The aim of this study is to evaluate the functional outcomes of patients with stroke and cancer